Manufacturing
'Licensed to Cure' for Olympus Tech
18 December 2012
Dassault Systèmes has announced that Olympus Technologies Singapore will be implementing the company’s 3DEXPERIENCE platform to support the development of its medical devices.
‘Licensed to Cure’ will be deployed to create a single working environment, allowing to eliminate scattered processes and data, and to “embed” regulations as an asset, optimising quality and compliance.
Dassault Systèmes’ 3DEXPERIENCE platform gives us centralised control and management of all product lifecycle information, enabling real time sharing and collaboration for all functions.
Lim HN, managing director, Olympus Technologies Singapore Olympus Technologies Singapore uses standard operating procedures for engineering development and software system documentation in their medical device manufacturing. The ‘Licensed to Cure’ solution will provide a single source of information, providing up-to-date information and create an accurate set of product data.
It is hoped that the new solution will reduce product-to-market time, as well as streamlining regulatory filings, developing the product development process and improving quality management.
“Dassault Systèmes’ 3DEXPERIENCE platform gives us centralised control and management of all product lifecycle information, enabling real time sharing and collaboration for all functions,” said Lim HN, managing director, Olympus Technologies Singapore. “Being able to combine engineering, quality, and regulatory compliance business processes, we have moved closer towards becoming the R&D and manufacturing centre of choice for our customers.”
“The shifting financial, regulatory and globalisation landscapes faced by medical devices manufacturers really call for a comprehensive business experience that can keep up with complexity, lower cost, quality, and compliance at once,” said Monica Menghini, executive vice president, Industry and Marketing, Dassault Systèmes. “Our new ‘Licensed to Cure’ industry solution experience is exactly meeting this challenge by allowing companies like Olympus Technologies Singapore to manage their business objectives in a complex regulatory environment while meeting consumers’ expectations for safe products.”
Add a comment